Developing manganese-enhanced MRI as a translational biomarker of cardiac regeneration

Effective translation of the therapeutics developed in REACT will require in vivo monitoring of safety and efficacy. MRI, CT and ultrasound have been used to follow cardiac function in clinical and preclinical trials of cell therapies but have not been …

Monitoring regenerative pathway activation in vivo

REACT will generate a range of therapies able to activate endogenous cardiac regeneration and cardiomyocyte proliferation. However, the lack of reliable in vivo methods for tracking cell cycle makes it challenging to study mechanisms and mediators of …

Leadership team

The REACT leadership team are responsible for all decisions related to the MRC/BHF CoRE in Advanced Cardiac Therapies. The leadership team is chaired by Professor Mauro Giacca , REACT Director, with support from Co-Directors Professor Andy Baker and …

Counteracting cardiac fibrosis through LNP-mediated microRNA delivery

Fibrosis underpins all forms of cardiac disease. Cardiac fibrosis ensues from an over-activation of cardiac fibroblasts upon cardiac injury and their differentiation into myofibroblasts. Fibroblast activation is initially of protective nature, but …